Drug Type Diagnostic radiopharmaceuticals, Radionuclide Drug Conjugates (RDC) |
Synonyms- |
Target |
Action inhibitors |
Mechanism PSMA inhibitors(Prostate-specific membrane antigen inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseIND Application |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Metastatic Prostate Carcinoma | Preclinical | United States | 20 Apr 2026 | |
| Metastatic Prostate Carcinoma | Preclinical | China | 20 Apr 2026 |





